Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
With the previous incumbent withdrawn from the market Ascendis hails a new hormone replacement for hypoparathyroidism.